Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research

Background Ovarian carcinomas consist of at least five distinct diseases: high-grade serous, low-grade serous, clear cell, endometrioid, and mucinous. Biomarker and molecular characterization may represent a more biologically relevant basis for grouping and treating this family of tumors, rather than site of origin. Molecular characteristics have become the new standard for clinical pathology, however development of tailored type-specific therapies is hampered by a failure of basic research to recognize that model systems used to study these diseases must also be stratified. Unrelated model systems do offer value for study of biochemical processes but specific cellular context needs to be applied to assess relevant therapeutic strategies. Methods We have focused on the identification of clear cell carcinoma cell line models. A panel of 32 “ovarian cancer” cell lines has been classified into histotypes using a combination of mutation profiles, IHC mutation-surrogates, and a validated immunohistochemical model. All cell lines were identity verified using STR analysis. Results Many described ovarian clear cell lines have characteristic mutations (including ARID1A and PIK3CA) and an overall molecular/immuno-profile typical of primary tumors. Mutations in TP53 were present in the majority of high-grade serous cell lines. Advanced genomic analysis of bona-fide clear cell carcinoma cell lines also support copy number changes in typical biomarkers such at MET and HNF1B and a lack of any recurrent expressed re-arrangements. Conclusions: As with primary ovarian tumors, mutation status of cancer genes like ARID1A and TP53 and a general immuno-profile serve well for establishing histotype of ovarian cancer cell We describe specific biomarkers and molecular features to re-classify generic “ovarian carcinoma” cell lines into type specific categories. Our data supports the use of prototype clear cell lines, such as TOV21G and JHOC-5, and questions the use of SKOV3 and A2780 as models of high-grade serous carcinoma.

[1]  D. Huntsman,et al.  Accelerating type‐specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high‐throughput tool for case review , 2013, Histopathology.

[2]  M. Köbel,et al.  The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors , 2013, Modern Pathology.

[3]  A. Tinker,et al.  Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas , 2013, The Journal of pathology.

[4]  D. Huntsman,et al.  The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer , 2012, The Journal of pathology.

[5]  B. Clarke,et al.  Prevalence of Loss of Expression of DNA Mismatch Repair Proteins in Primary Epithelial Ovarian Tumors , 2012, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[6]  Y. Nakamura,et al.  Dominant Expansion of a Cryptic Subclone with an Abnormal Karyotype in B Lymphoblastoid Cell Lines during Culture , 2012, Cytogenetic and Genome Research.

[7]  Christopher Korch,et al.  DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. , 2012, Gynecologic oncology.

[8]  Thomas Zeng,et al.  Use of mutation profiles to refine the classification of endometrial carcinomas , 2012, The Journal of pathology.

[9]  M. Stratton,et al.  Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes , 2012, The Journal of pathology.

[10]  J. George,et al.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  I. Shih,et al.  Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma , 2012, Cancer.

[12]  D. Bowtell,et al.  The changing view of high-grade serous ovarian cancer. , 2012, Cancer research.

[13]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[14]  D. Gershenson.  Treatment of ovarian cancer in young women. , 2012, Clinical obstetrics and gynecology.

[15]  Sohrab P Shah,et al.  BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma , 2012, Modern Pathology.

[16]  H. Tsuda,et al.  Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas , 2012, Modern Pathology.

[17]  G. Ning,et al.  Fallopian Tube Correlates of Ovarian Serous Borderline Tumors , 2011, The American journal of surgical pathology.

[18]  S. Bulun,et al.  Endometriosis and Ovarian Cancer: A Review of Clinical, Pathologic, and Molecular Aspects , 2011, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[19]  Jason D. Wright,et al.  Natural history and outcome of mucinous carcinoma of the ovary. , 2011, American journal of obstetrics and gynecology.

[20]  Kylie L. Gorringe,et al.  Copy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification? , 2011, Clinical Cancer Research.

[21]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[22]  W. McCluggage,et al.  Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. , 2011, Pathology.

[23]  H. Tsuda,et al.  Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient , 2011, Modern Pathology.

[24]  D. Huntsman,et al.  Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites. , 2011, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[25]  I. Shih,et al.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.

[26]  J. George,et al.  The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene , 2011, Oncogene.

[27]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[28]  H. Mackay,et al.  Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. , 2011, Gynecologic oncology.

[29]  Süleyman Cenk Sahinalp,et al.  deFuse: An Algorithm for Gene Fusion Discovery in Tumor RNA-Seq Data , 2011, PLoS Comput. Biol..

[30]  S. Leung,et al.  Calculator for ovarian carcinoma subtype prediction , 2011, Modern Pathology.

[31]  A. Ashworth,et al.  Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas , 2011, Clinical Cancer Research.

[32]  Kylie L. Gorringe,et al.  IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer , 2011, Clinical Cancer Research.

[33]  N. Le,et al.  Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  N. Auersperg.  The Origin of Ovarian Carcinomas: A Unifying Hypothesis , 2011, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[35]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[36]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[37]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[38]  A. Reuss,et al.  The biological and clinical value of p53 expression in pelvic high‐grade serous carcinomas , 2010, The Journal of pathology.

[39]  Amanda Capes-Davis,et al.  Check your cultures! A list of cross‐contaminated or misidentified cell lines , 2010, International journal of cancer.

[40]  M. Nucci,et al.  Serous Tubal Intraepithelial Carcinoma: Diagnostic Reproducibility and its Implications , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[41]  Samuel Leung,et al.  Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible: A Transcanadian Study , 2010, The American journal of surgical pathology.

[42]  D. Huntsman,et al.  Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[43]  Carlos Caldas,et al.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.

[44]  I. Shih,et al.  DNA Copy Numbers Profiles in Affinity-Purified Ovarian Clear Cell Carcinoma , 2010, Clinical Cancer Research.

[45]  A. Reuss,et al.  Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer , 2010, International Journal of Gynecologic Cancer.

[46]  Ie-Ming Shih,et al.  The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.

[47]  N. Horowitz,et al.  When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. , 2010, Gynecologic oncology.

[48]  A. Mes-Masson,et al.  Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma , 2010, The Journal of pathology.

[49]  J. Marto,et al.  Primary ex-vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis , 2009, Oncogene.

[50]  D. Huntsman,et al.  Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. , 2010, Gynecologic oncology.

[51]  Anna Adamiak,et al.  HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy , 2009, BMC Cancer.

[52]  I. Shih,et al.  Ovarian Low-grade and High-grade Serous Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems , 2009, Advances in anatomic pathology.

[53]  V. Velculescu,et al.  Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. , 2009, The American journal of pathology.

[54]  C. Crum.  Intercepting pelvic cancer in the distal fallopian tube: Theories and realities , 2009, Molecular oncology.

[55]  Marketa Zvelebil,et al.  PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas , 2009, Clinical Cancer Research.

[56]  D. Huntsman,et al.  A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary , 2009, The American journal of surgical pathology.

[57]  Afshin Mashadi-Hossein,et al.  Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter™ Assay System , 2009, BMC Research Notes.

[58]  S. Leung,et al.  Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.

[59]  J. Seidman,et al.  Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors. , 2008, Archives of pathology & laboratory medicine.

[60]  R. Tothill,et al.  Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors , 2008, Molecular Cancer Research.

[61]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[62]  Nhu Le,et al.  Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. , 2008, Human pathology.

[63]  K. Jensen,et al.  Microsatellite Instability and Mismatch Repair Protein Defects in Ovarian Epithelial Neoplasms in Patients 50 Years of Age and Younger , 2008, The American journal of surgical pathology.

[64]  H. Gabra,et al.  Endometrioid epithelial ovarian cancer , 2008, Cancer.

[65]  R. Soslow,et al.  Histologic subtypes of ovarian carcinoma: an overview. , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[66]  D. Bodurka,et al.  Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. , 2008, Gynecologic oncology.

[67]  A. Måsbäck,et al.  Ovarian cancer at young age: the contribution of mismatch‐repair defects in a population‐based series of epithelial ovarian cancer before age 40 , 2007, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[68]  R. Drapkin,et al.  Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer , 2007, Clinical Medicine & Research.

[69]  Barry Rosen,et al.  Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. , 2006, Journal of the National Cancer Institute.

[70]  M. Scotté,et al.  Mixed Clear Cell and Endometrioid Carcinoma Arising in Parietal Endometriosis , 2006, Gynecologic and Obstetric Investigation.

[71]  I. Tomlinson,et al.  Molecular genetic evidence that endometriosis is a precursor of ovarian cancer , 2006, International journal of cancer.

[72]  N. Natarajan,et al.  Ovarian cancer incidence in the United States, 1992-1999. , 2005, Gynecologic oncology.

[73]  Colleen A Crane,et al.  Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[74]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[75]  R. Broaddus,et al.  Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. , 2004, Human pathology.

[76]  M. Gore,et al.  Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  R. Broaddus,et al.  Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer , 2004, Modern Pathology.

[78]  J. Inazawa,et al.  Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[79]  I. Jacobs,et al.  Histopathologic Features of Genetically Determined Ovarian Cancer , 2002, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[80]  A. Whittemore,et al.  Survival among U.S. women with invasive epithelial ovarian cancer. , 2002, Gynecologic oncology.

[81]  K. Strait,et al.  Identification of a p53 Response Element in the Promoter Region of the hMSH2 Gene Required for Expression in A2780 Ovarian Cancer Cells* , 2001, The Journal of Biological Chemistry.

[82]  M. Wells,et al.  Precursor lesions of ovarian epithelial malignancy , 2001, Histopathology.

[83]  E. Thomas,et al.  Endometriosis: candidate genes. , 2001, Human reproduction update.

[84]  E. Thomas,et al.  Molecular Genetic Defects in Endometriosis , 2000, Gynecologic and Obstetric Investigation.

[85]  E. Thomas,et al.  Evidence that Endometriosis Behaves in a Malignant Manner , 2000, Gynecologic and Obstetric Investigation.

[86]  A. Monks,et al.  Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen , 2000, Cancer Chemotherapy and Pharmacology.

[87]  S. Tsugane,et al.  Observer disagreement in histological classification of ovarian tumors in Japan. , 1994, Gynecologic oncology.

[88]  S. Silverberg,et al.  Ovarian tumors associated with atypical endometriosis. , 1988, Human pathology.

[89]  T. Ulbright,et al.  Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. With emphasis on methodology. , 1987, Archives of pathology & laboratory medicine.

[90]  T. Parmley,et al.  Interobserver variability in the interpretation of epithelial ovarian cancer. , 1984, Gynecologic oncology.

[91]  P. Disaia,et al.  Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors. , 1972, American journal of obstetrics and gynecology.